Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,018 total articles
Nike is trading below key moving averages after a pullback that priced in tariff headwinds and softer China demand. With a $92.5B market cap, $2.48B of free cash flow and a 2.46% dividend yield, the balance sheet and brand give Nike room to recover. Catalysts over the next 3-6 months - including a Supreme Court ruling easing tariff risk (02/23/2026…
Bloom Energy is trading as a high conviction play on AI data-center power reliability. The company showed 37% revenue growth in 2025 to $2.0B, Q4 revenue of $777.7M and a reported $20B backlog, and it is guiding to roughly $3.1B in 2026. Valuation is rich (market cap ~$42.4B, P/S ~20.5, EV/S ~20.65) and leverage is meaningful, but accelerating dema…
Novo Nordisk shares cratered into a 52-week low after REDEFINE 4 failed to show non-inferiority versus Eli Lilly's tirzepatide. The market reaction is severe and technical momentum is decisively bearish. This trade idea outlines a tactical short with a precise entry at $40.605, a protective stop at $45.00 and a downside target at $34.00 over a mid-…
BNEFF is trading at $3.77 with improving moving averages, rising RSI (58.5) and a stretched short-interest profile (828,438 shares short as of 01/30/2026). For active traders willing to accept OTC liquidity and execution risk, a controlled long into confirmed strength offers an asymmetric payoff: upside to $4.50 within a 45-trading-day window again…
Prada's reported purchase of Versace and progress on tech collaborations have rattled the stock but the deal size (~$1.375B) is under 10% of Prada's $14.1B market cap and should be manageable. Technicals and margin tailwinds leave room for a mid-term bounce toward $14. A disciplined entry at $11.00 with a $9.90 stop and a $14.00 target provides a d…
InnovAge (INNV) has been through litigation and volatility; recent moves suggest much of the bad news is already priced into the stock. Revenue growth and improving margins give a plausible path to upside, but high valuation multiples and regulatory sensitivity make this a medium-risk trade. Enter on weakness, size carefully, and use a defined stop…
Astera Labs' connectivity silicon for data-center and AI systems has been punished with the broader AI hardware downturn. For disciplined, patient buyers willing to accept execution and execution-risk, the current environment offers an asymmetric opportunity: limited near-term upside priced in, long-term upside tied to secular AI and hyperscaler up…
Apple is a cash-generating machine built around a 2.5 billion installed base. Valuation is rich but reasonable given $123B free cash flow and a durable services ramp. We outline a mid-term swing trade that captures upside from product cycles and services momentum while limiting downside with a tight stop.
Novo Nordisk (NVO) has been hammered on trial headlines and short-term fears, but underlying demand for weight-loss therapies and expanding oral formulations support a mid-term trade. At $47.42 the stock reflects pessimism about 2026 sales that may already be priced in. This trade targets a rebound as Wegovy adoption steadies and market growth expe…
Alphabet is investing heavily in AI infrastructure and that shows up in higher capex talk. Don’t confuse temporary spend with impaired economics: the company still generates $73.3B of free cash flow, trades at ~29x earnings, and Google Cloud growth is re-accelerating. This trade targets a rebound toward the 52-week highs as AI monetization and ente…
I argue Alphabet (GOOGL) is a tactical buy over the next 45 trading days. The SpaceX IPO and high-profile long-duration bond issuance are likely to shift investor allocations and long-term rates in ways that favor growth-with-quality names. Alphabet’s core advantages - pervasive distribution, cloud and AI infrastructure, and entrenched ad marketpla…
Hemisphere Energy (HMENF) is an OTC energy name trading near $1.62 with steady technical momentum, limited days-to-cover short interest, and recent volume spikes that suggest institutional size moves are unlikely to blow the stock around. For retirees or conservative allocators who want a modest allocation to small-cap energy, this is a structured …
The headline chart for Continental (CTTAY) understates the company's operational momentum after a corporate separation. Adjusted for the spin-off, technicals are bullish, industry secular growth in ADAS and vehicle electrification supports higher earnings, and OTC positioning provides a favorable risk/reward for a mid-term swing trade. Entry $8.70,…
PTC Therapeutics is transitioning from royalty receipts to product-led growth centered on Sephience (PKU). With a market cap near $5.7B, strong free cash flow generation and an undemanding EV/EBITDA multiple, PTCT offers a structured long opportunity: entry $70.60, target $95.00, stop $58.00, trade horizon 180 trading days.
ServiceNow is trading near its 52-week low after a sector-wide AI-driven sell-off. Fundamentals remain intact: $109B market cap, $4.58B in free cash flow, solid return metrics and low leverage. Technicals show oversold conditions and improving momentum. This trade idea is a long biased play to capture re-rating as customers adopt ServiceNow to mana…
Visa remains one of the highest-quality, capital-light global payment networks. With $22.9B in free cash flow, ROE near 44%, and a market cap around $612B, the company combines defensive economics with durable growth. Recent multiple compression creates a buying opportunity for investors targeting total return over the next 6-9 months, provided reg…
Anterix (ATEX) offers a mid-cap exposure to 900 MHz private wireless for utilities that now shows both fundamental underpinnings and bullish technical momentum. The company is profitable (EPS $4.34) with a low P/E (~8.3) and enterprise value roughly in line with market cap ($643M EV vs ~$672M market cap). FCC rulemaking, a $250M AnterixAccelerator …
Masco is executing operationally, generating meaningful free cash flow and sitting in a housing-linked recovery. At current levels the stock offers a reasonable entry for a long trade: attractive FCF yield, mid-teens P/E, supportive technicals and manageable balance-sheet metrics. We lay out an actionable trade with entry, stop and target, plus the…
Fastenal (FAST) is a high-ROE, cash-generative industrial distributor that merits a long-term allocation, but the market currently prices a lot of growth into the shares. The trade here is to initiate a long position on weakness with a clear stop and a realistic target tied to continued margin expansion and steady free-cash-flow growth.
Reddit (RDDT) just served a clear reminder that its growth engine is intact: 70% revenue growth in the last quarter, robust free cash flow and a partnership that monetizes its vast audience. The shares have been punished on user-growth concerns and multiple compression, creating a reward-to-risk setup for a long trade. My plan: enter at $150.14, st…
Nebius is at the center of the AI cloud infrastructure boom. Strong ARR conversion, rapid revenue acceleration and aggressive capacity builds make it an asymmetric trade for traders willing to accept execution and financing risk. Enter at $98, stop $86, target $150 over a mid-term horizon (45 trading days).
Blackstone Mortgage Trust (BXMT) is trading below book at $19.52 with a near-10% yield. Recent moves to shift the portfolio toward agency-friendly multifamily loans, a partnership with M&T on agency financing, and improving free cash flow make a compelling case to upgrade the rating to buy. The equity remains levered and sensitive to rates, so the …
iShares MSCI EAFE Small-Cap ETF (SCZ) offers a pragmatic long: current momentum and a 2.48% yield give a cushion while a potential re-rating of EAFE small-caps could drive upside. Trade with strict stops and clear time horizons.
Opus Genetics is a speculative long trade targeting asymmetric upside from clinical progress in two inherited retinal disease programs - LCA5 and BEST1. With outcomes driven by near-term clinical readouts, limited patient populations, and high per-patient economics, the setup favors a position-sized long where downside is controlled by a clear stop…
Blue Owl (OWL) is trading near its 52-week low after headlines about halted redemptions and an alleged financing miss. The sell-off has driven technicals into oversold extremes (RSI ~25.7) and produced heavy short activity, while core fundamentals (roughly $1.2B in free cash flow and a market cap near $16.9B) imply a meaningful FCF yield. This trad…
